Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 13, 2025

My Top 10 Stocks to Buy for 2026

View original at nasdaq.com
My Top 10 Stocks to Buy for 2026 Key Points Together, these stocks offer you a balanced mix of growth and safety…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Meta is committed to investing in AI and using it to supercharge revenue in the years to come

    80% confidence
  • Millennials and Gen-Z made up 64% of new accounts in latest quarter

    80% confidence
  • AI models will continue to rely on chips to power them through their job of applying AI to real-world problems

    80% confidence
  • AI infrastructure spending may reach into the trillions of dollars over the next five years

    80% confidence
  • The 10 best stocks identified by analyst team could produce monster returns in coming years

    80% confidence
  • Viking could emerge as a new winner in weight loss market in a few years with candidates functioning same way as Lilly and Novo drugs

    80% confidence
  • Stock Advisor's total average return is 972% compared to 195% for S&P 500

    80% confidence
  • Bull markets usually last much longer than bear markets

    80% confidence
  • These 10 stocks offer a balanced mix of growth and safety spanning multiple industries with many market leaders

    80% confidence
  • There's room for other players to carve out share in weight loss drug market despite Lilly and Novo dominance due to high demand

    80% confidence
  • High-income individuals continue spending regardless of economic situation resulting in steady earnings growth for American Express

    80% confidence

Data points we hold from this source

Amazon Web Services · revenue run rate132 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
My Top 10 Stocks to Buy for 2026 — Source | Via News | ViaNews Market